Nasdaq gnlx.

WESTLAKE VILLAGE, Calif. - Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000 Index and small-cap Russell 2000 at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.Jul 6, 2023 · The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 32.13 / share. This is an increase of 80.00% from the prior estimate of 17.85 dated June 1, 2023. Genelux Corp. GNLX (U.S.: Nasdaq). REAL TIME 3:03 PM EST 11/30/23. $11.81USD ... GNLX. Significant News Only. No significant news for GNLX in the past two years ...Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...WebWESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO ...Web

WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery ...

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...Genelux Corporation Common Stock (GNLX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

Yong Yu, VP at Genelux GNLX, reported a large insider sell on November 22, according to a new SEC filing. Genelux shares are trading up 7.9% at $11.2 at the time of this writing on Thursday ...Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...WebGenelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily ...

View real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...

Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact. Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients. LEARN MORE.Genelux (NASDAQ: GNLX) is owned by 15.88% institutional shareholders, 5.64% Genelux insiders, and 78.48% retail investors. Aladar Szalay is the largest individual Genelux shareholder, owning 555,000.00 shares representing 2.08% of the company. Aladar Szalay's Genelux shares are currently valued at $6.21M.Winners. The top five IPOs of 1H 2023 are as follows (as of Jun 30, 2023): Genelux Corporation (GNLX), which went public on Jan 26, 2023, at $6.00 per share and has since increased to $32.72 ...WebWESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...Given GNLX’s positive Phase 2 trial results to-date, my outlook on IPO is a Buy for patient, risk-tolerant life science investors with a long-term hold time frame. ... (NASDAQ:GNLX) was founded ...

Jul 28, 2023 · Shares of Genelux ( GNLX -7.61%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ... 26. 10. 2023 ... Genelux raised $15.9 million in January pricing shares at $6 each. The stock (NASDAQ:GNLX) closed at $18.69 on Oct. 25, a 211.5% increase. Also ...Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.WebGenelux Corporation's (NASDAQ:GNLX) value has fallen 16% in the last week, but insiders who sold US$11m worth of stock over the last year have had less success. Insiders might have been better off holding onto their shares, given that the average selling price of US$23.49 is still below the current share price.Check if GNLX Stock has a Buy or Sell Evaluation. GNLX Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Genelux Corporation News.The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 32.13 / share. This is an increase of 80.00% from the prior estimate of 17.85 dated June 1, 2023.

FN Media Group Presents USA News Group News Commentary . Vancouver, BC – October 11, 2023 – USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer …The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ...

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...Shares of Genelux ( GNLX 12.02%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ...WebU.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Tuesday. Here are some big stocks recording gains in today’s session. Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA ...Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...WebWESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...

Genelux (NASDAQ:GNLX) director Szalay Aladar continued to dispose of his stake in the biopharmaceutical company. Aladar sold 42,263 shares of indirect ownership, held by The Szalay 2010 Retained ...

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, …

Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...Based on analysts offering 12 month price targets for GNLX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your ...57.59%. Get the latest Genelux Corp (GNLX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …GNLX Genelux Corporation Genelux Corporation Announces Pricing of Initial Public Offering. WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation ('Genelux' or 'the ...About This Event Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for ...So far, 2023 has been a great year for Genelux Corporation (NASDAQ:GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that’s primarily ...The latest price target for . Dyne Therapeutics (NASDAQ: DYN) was reported by JP Morgan on Wednesday, August 9, 2023.The analyst firm set a price target for 22.00 expecting DYN to rise to within ...Back to GNLX Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Genelux | 726 followers on LinkedIn. Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of …Genelux Corporation ( Nasdaq: GNLX ), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering ...Instagram:https://instagram. stock trading schools near meiblctop rated gold stocksbest dividend yielding stocks Genelux Stock Price, News & Analysis (NASDAQ:GNLX) $11.90 +0.20 (+1.71%) (As of 11/30/2023 ET) Compare Today's Range $11.46 $12.00 50-Day Range …NASDAQ does not use this value to determine compliance with the listing requirements. Inpixon Common Stock (INPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global ...Web stock watchlist for tomorrowroyalty trust stocks Genelux Corporation ( NASDAQ: GNLX) has filed to raise $30 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing ...Web chromadex Winners. The top five IPOs of 1H 2023 are as follows (as of Jun 30, 2023): Genelux Corporation (GNLX), which went public on Jan 26, 2023, at $6.00 per share and has since increased to $32.72 ...View real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: …Nov 29, 2023 · GNLX is trading at a 48% discount. Price $11.68. Nov 29, 2023. Fair Value $23.17. Nov 29, 2023 ... Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)